Dec 29, 2022 / 01:00PM GMT
Operator
Good morning, and welcome to Ardelyx's conference call. (Operator Instructions) As a reminder, today's call is being recorded. I would now like to turn the call over to Caitlin Lowie, Vice President, Corporate Communications and Investor Relations. You may begin.
Caitlin Lowie -
Thank you, and good morning, everyone. This morning, we issued a press release announcing the FDA Office of New Drugs' decision regarding the New Drug Application, or NDA for XPHOZAH from the Cardiovascular and Renal Drugs Advisory Committee meeting convened on November 16, 2022.
During this call, we will refer to today's press release which is available on the Investors section of the company's website at ardelyx.com. On the call with me today with prepared remarks are Mike Raab, President and CEO; and Susan Rodriguez, Chief Commercial Officer. Dr. Laura Williams, Chief Medical Officer; Justin Renz, Chief Financial Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer will join us for the question-and-answer period.
During this call, we will be
Ardelyx Inc Update Call Transcript
Dec 29, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers